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Cancer chemotherapy, particularly one usingregimens employing high-dose cytotoxic 
drugs such as cyclophosphamide (CTX), has been considered to be immune 
suppressive[Ed1]. On the contraryHowever, we observed that a single administration of 
high-dose CTX administration abolished the tumors arising from subcutaneous injection 
of a mouse hepatoma cell line, and subsequently induced specific tumor immunity. The 
aAbsence of T cells or Ddepletion of T cells, specifically CD4+ T cells, abrogated the 
CTX-mediated tumor regression[Ed2]. CTX treatment induced the rapid recruitment of 
CD4+ T cells into the tumors, and these recruited cells started toinitiated expression of 
LAMP1/CD107a, a cytotoxic granule molecule, LAMP1/CD107a, and granzyme B 
without in the absence of antigen presentation at draining lymph nodes and proliferation 
in the tumor tissues. Moreover, CTX enhanced the expression of a CC chemokine, 
CCL3, in tumor tissues, and CTX-mediated tumor regression was attenuated in mice 
deficient in CCR5, the receptor for this chemokine. Consistently, less lessreduced 
CTX-induced accumulation of intratumoral LAMP1/CD107a-expressing CD4+ T cells 
was less observed in mice receiving splenocytes derived from CCR5-deficient 
mouse-derived splenocytesmice than in those receiving splenocytes derived from WT 
mouse-derived splenocytesmice. Thus, CTX induces the expression of CCL3 to, which 
induces the intratumoral migration of CD4+ T cells with expressing cytotoxic molecules 
to induce , leading to tumor eradication and subsequent specific tumor immunity. 
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1. Introduction 
 Cyclophosphamide (CTX) is oxidized to 4-hydroxycyclophosphamide, [1], 
which enters cells and spontaneously decomposes to phosphoramide -mustard. At a 
physiological pH of 7.4, this component generates causes covalent linkage of DNA 
alkyl groups of the DNA [2]. The resultant inter-strand crosslink creates 
denaturation-resistant DNA fractions, thereby inhibiting DNA replication and leading to 
subsequent apoptosis [3]. CTX exerts itsThe cytotoxic action of CTX is exerteds against 
highly -proliferativeng cells, particularly lymphocytes , as well asand cancer cells, 
thereby depletingcausingand causes the depletion of lymphocytes in from the peripheral 
blood and tissue [4]. Consequently, CTX, particularly at its  high -doses (100 to 200 
mg/kg), has been employed as one of the most potent immune osuppressive drugs to 
combat life-threatening autoimmune diseases and to prevent graft-versus-host disease 
after allogenic bone marrow transplantation [5]. 
 Regulatory T cells (Tregs), characterized by the expression of CD4, CD25, and 
Foxp3, accumulate in tumor tissues of both tumor-bearing humanspatients as well as 
and in those of mice and can contribute to immune tolerance to cancer cells[Ed3] [6]. A 
Llow -doses of CTX can deplete Tregs in the blood and lymphoid organs of 
tumor-bearing mice and decrease cause a decrease in the number of Tregs that 
infiltrating infiltrate tumor tissues [7, 8]. The This decrease in infiltrating Tregs can 
[Ed4] improve the ability of cytotoxic T cell- and/or NK cell-mediated antitumor 
immunity, not only in tumor-bearing mice but also in advanced cancer patients [9]. 
Moreover, low-dose CTX can induce the polarization from of Th2 to Th1 and can 
eventually exert anti-metastatic effects [10]. Recent observations have suggested that a 
single high -dose of CTX can induce specific tumor immunity [11]. Hence, we 
examined the effects of a single high -dose of CTX on the tumors arising from 
subcutaneous injection of a mouse hepatoma cell line.;, and provedWwe demonstrate 
that it high-dose CTX can eradicate the tumors in a T cell-dependent (, depending on T 
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cells, particularly CD4+ T onescell) manner., in contrast totOur results contrast with the 
widely -held view that a high-dose CTX can be immune osuppressive. 
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2. Materials and Methods 
2.1 Mice 
Specific pathogen-free male five5- to seven7-week old BALB/c mice (WT mice) and 
BALB/c-nu mice (nude mice) were purchased from Charles River Japan [Ed5] . 
CCR5-deficient (CCR5-/-) mice were backcrossed with BALB/c mice for more than 
eight8 generations [12]. CD45.1 BALB/c congenic mice were obtained from the 
Jackson Laboratories (Bar Harbor, ME). All mice were kept maintained under the 
specific pathogen-free conditions. All animal experiments were approved and performed 
according to the Guideline for the Care and Use of Laboratory Animals of Kanazawa 
University.  
 
2.2 Tumor cell line 
A murine hepatocellular carcinoma (HCC) cell line, BNL 1ME A.7R.1 (BNL), was 
purchased from the American Type Culture Collection and kept maintained at low 
passage throughout the study. The cells were cultured as previously described [13]. 
 
2.3. Tumor injection 
The left flanks of eight8-week old male WT, nude, or CCR5-/- mice were 
subcutaneously (s.c.) inoculated subcutaneously (s.c.) with 5 × 105 BNL cells in 100 µL 
of PBS. Tumor sizes were evaluated three times a week using calipers, and tumor 
volumes were calculated by using the following formula: Tumor volume (mm3) = (the 
longest diameter) × (the shortest diameter) × (depth) /2. When the tumor volume 
became reached 40 to 80 mm3, the mice were intraperitoneally (i.p.) injected with 150 
mg/kg CTX (Figure 1 A). In some experiments, mice were i.p. injected with anti-CD4 
(GK1.5, 100 μg/bodyanimal) or anti-CD8 antibody (53.6.7, 200 μg/bodyanimal), twice 
on[Ed6] Day 1 and 14 (Figure 1D). In another series of experiments, at 30 days after the 
first BNL inoculation of BNL cells into, the mice, the animals whose tumors had 
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completely disappeared regressed after the treatment, were inoculated again with 5 × 
105 BNL cells and 2.5 × 105 colon 26 (Col26, a murine colon carcinoma cell line) cells 
into the right and left flank, respectively. As a control, WT mice were inoculated with 
200 μl of PBS into the left flank instead of the first BNL inoculation. The day of the 
second BNL inoculation was determined designated as day 0.  
 
2.4. Adoptive transfer of splenocytes 
Single cell populations were obtained from the spleens of CD45.1 congenic WT mice, 
and were then the cells were labeled with 2 μM of carboxyfluorescein diacetate, 
succinimidyl ester (CFSE, Life Technologies Inc.). Ten million CFSE-labeled cells in 
200 μl of PBS were intravenously transferred to CD45.2 WT mice intravenously via the 
tail vein one day after CTX administration (Figure 3A). Similarly, 1 x 107 CFSE-labeled 
splenocytes from CCR5-/- mice were intravenously injected intravenously into the tail 
vein one day after CTX administration (Figure 5A).  
 
2.5. Flow cytometry (FCM) 
Single cell suspensions were prepared from tumors, draining lymph nodes (dLNs), and 
spleens as previously described [13] and were stained with various combinations of 
phycoerythrin (PE)-labeled anti-LAMP1/CD107a, allophycocyanin (APC)-labeled 
anti-CD4, or fluoresceinfluorescence isothiocyanate (FITC)-labeled anti-CD8 antibody 
(BD Biosciences). FITC-rat IgG, PE-rat IgG, or APC-rat IgG (BD Biosciences Japan) 
were used as negative controls. The eExpression of each molecule was determined as 
previously described [14]. 
 
2.6. Quantitative (q)RT-PCR 
qRT-PCR was done performed to quantify the chemokine mRNA of chemokines as 
previously described [12]. Hypoxanthine phosphoribosyltransferase (HPRT) or 
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glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was amplified as an internal 
control. The nucleotide sequences of the used primers used were are described in Table 
1. 
 
2.7. Determination of intratumoral chemokine contents 
Protein lysates were obtained from frozen tumor tissues, and their the protein 
concentrations were determined as previously described [12].  CCL3 and CCL4 
levels Then,were then measured in the protein lysates were used for the determination 
ofto measure CCL3 and CCL4 by using specific enzyme-linked immunosorbent assay 
(ELISA) kits (R&D Systems) according to the manufacturer’s instructions. 
 
2.8. DoubleTwo-color immunofluorescence analysis 
Resected tumor tissues were processed for doubletwo-color immunofluorescence 
analysis as previously described [12]. The obtained sections were incubated with 
optimally -diluted rat anti-granzyme B (eBioscience) or isotype-matched control 
antibodies, and thenand subsequently incubated with the optimally diluted Alexa Fluor 
488 Donkey anti-rRrat IgG antibody (Life Technology Inc.). Finally, the sections were 
incubated with optimally -diluted Alexa Fluor 594-conjugated anti-CD4 or 
isotype-matched control antibody (BioLegend). Immunofluorescence was visualized on 
a Keyence BZ-X7100 (Keyence Japan). 
 
2.8. Statistical analysis 
The dData were statistically analyzed statistically using the methods indicated in each 
figure legend. p < 0.05 was considered  statistically significant. 
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3. Results 
3.1. CD4+ T cells are indispensable to in CTX-mediated eradication of BNL 
tumors.  
Although an immune response is presumed to be involved in continuous low-dose 
chemotherapeutics-induced mediated tumor eradication regression [7] [9, 15], the roles 
of anthe immune response in tumor eradication induced by a single high -dose of a 
chemotherapeutics it still remains to be investigated on the roles of immune response in 
tumor eradication induced by a single high-dose of chemotherapeutics. In order Tto 
address this question, we examined the process of tumor eradication regression caused 
by a single administration of a high -dose of CTX. We observed that CTX (at doses of 
100 mg/kg or lower) [Ed7]failed to eradicate the formed tumors established tumors 
arising resulting from by subcutaneous injection of BNL cells up to 100 mg/kg 
(Supplementary Figure S1).  On the contraryIn contrast, 150 mg/kg CTX completely 
eradicated the tumors in most of the WT mice (Figure 1 B). Moreover, WT mice whose 
tumors had disappeared after CTX treatment rejected re-challenged BNL cells, but not 
cells from an unrelated murine colorectal cancer cell line, Col26 (Figure 1C). These 
observations would indicate that a single high -dose of CTX could can induce specific 
tumor immunity as well as tumor abolitionablation. In support of this notion, in vitro 
treatment with mafosfamide, (an active compound of derived from CTX), induced 
immunogenic apoptosis in BNL cells, as evidenced by calreticulin exposure and high 
mobility group box-1 secretion [16] (Supplementary Figure S2). Furthermore, all nude 
mice exhibited a transient decrease in tumor size but followed by [Ed8]a subsequent 
progressive increase in tumor sizes upon treatment with the same dose [Ed9]of CTX 
(Figure 1B), while treatment with an anti-CD4 antibody but not  an anti-CD8 antibody 
treatment significantly reducedinhibited the CTX-mediated tumor regression (Figure 




3.2. CD4+ T cells at the tumor site Expression ofdisplay cytotoxic phenotypes by 
CD4+ T cells in at the tumor site.  
FCM analysis revealed that CTX treatment induced the appearance expression of a 
cytotoxic granule membrane protein, LAMP1/CD107a, in-expressing CD4-positive or 
CD8-positive cells in tumor tissues but not in dLNs and or the spleens (Figure 2A). Of 
interestNotably, is that LAMP1/CD107a expression was consistentlyconstantly higher 
in intratumoral CD4+ cells than in CD8+ ones cells (Figure 2B).  LAMP1/CD107a 
translocates to the cell membrane in cytotoxic cells upon release of granzyme B or 
perforin, which mediate the cytotoxic effects of these cells. [Ed10] Cytotoxic cells 
translocate LAMP1/CD107a to cell membrane, when they release granzyme B or 
perforin to exhibit their cytotoxicity [17].  Hence, we examined evalulated the 
expression of these molecules[Ed11]. CTX treatment enhanced caused an increase in 
granzyme B and perforin mRNA expression (Figure 2C), and granzyme B was detected 
in intratumoral CD4+ cells three  3 days after CTX administration (Figure 2D). Thus, 
CTX treatment increased the expression of cytotoxic molecule-expressings in CD4+ T 
cells[Ed12] within tumors and subsequently eradicatedled to  BNL tumor regressions. 
 
3.3. Direct migration of Ccirculating CD4+ T cells directly migrate into the tumor 
site.  
To delineate the mechanisms underlying the increase in CD4+ T cells with expressing 
cytotoxic molecules within tumors, we conducted performed adoptive transfer 
experiments (Fgiure Figure 3A). Dilution of CFSE dilution, which indicates 
proliferation, was observed in draining lymph nodes  at only sevenat 7 days after CTX 
injection (Figure 3B). Non-proliferating CFSE-labeled CD4+ T cells appeared in the 
tumor but without proliferation, at four  4 days day 4 after CTX treatment, whereas 
some proliferating CD4+ T cells proliferated at day 7were observed seven  7 days after 
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CTX treatment (Figure 3B). Thus, at day 4 after CTX administration when the tumors 
started to regress four  on day 44 days after CTX administration, circulating CD4+ T 
cells were recruited into the tumors (without in the absence of antigen priming at dLN) 
and the proliferation inbegan proliferating to proliferate at the tumor sites. 
[Ed13]Furthermore, the expression levels of LAMP1/CD107a was expressed to awere 
similar extent by in intratumoral CFSEhigh non-proliferating CD4+ T cells at on days 4 
and at day 7, and in CFSElow proliferating CD4+ T cells at on day 7 (Figure 3C), 
suggesting that CD4+ T cells in tumors can release cytotoxic granules. Given that the 
levels of LAMP1/CD107a were negligible in circulating CD4+ T cells expressed a 
negligible level of LAMP1/CD107a (Supplementary Figure S3), LAMP1/CD107a 
expression was initiatedinduced upon migration of CD4+ T cells started to express 
LAMP1/CD107a after migrating into the tumor sites.[Ed14] 
 
3.4. Crucial roles of CCR5-expressing cells play crucial roles in CTX-mediated 
tumor eradication. 
To understand the mechanism underlying the early phase of intratumoral CD4+ T cell 
recruitment in the early phase, we examined the mRNA expression levels of several 
chemokines in the tumor tissue three  3 days after CTX administration. Among the 
chemokines that we examined, CCL3 and CCL4 mRNA expression was significantly 
up-regulated while CCL2 and CCL5 mRNA did not change significantly (Figure 4A to 
D). Moreover, CTX treatment significantly increased intratumoral CCL3 but not CCL4 
contents levels significantly (Figure 4E and F). Although CCR1 and CCR5 are receptors 
for CCL3, we have previously observed that tumor-infiltrating CD4+ and CD8+ T cells 
expressed CCR5 but not CCR1 [18]. Thus, we inoculated BNL cells into CCR5-/- and 
WT mice a[Ed15]nd subsequently treated the animals with CTX (Figure 1A). Tumors in 
CCR5-/- mice recurred with a significantly higher frequency in CCR5-/- mice than those 
in WT mice (Figure 5A). These observations would indicate the involvement of 
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CCR5-expressing cells in CTX-mediated tumor regression. We nextNext, we 
intravenously injected intravenously CFSE-labeled splenocytes from WT- or 
CCR5-/- mouse-derived mouse splenocytesmice into tumor-bearing WT mice 1 day after 
CTX injection and removed ; the tumors were then removed four  at 4 days after CTX 
injection (Figure 5B). CD4+ splenocytes obtained from both WT and CCR5-/- mice did 
not express LAMP1/CD107a (Supplementary Figure S3). However, the expression of 
LAMP1/CD107a expression in intratumoral CD4+ T cells expressed 
LAMP1/CD107awas more abundantlyhigher in mice receiving WT mouse-derived 
splenocytes, compared with than in those receiving CCR5-/- mouse-derived ones 
splenocytes (Figure 5C and D). Thus, CTX enhances the expression of CC chemokines 
to induce intratumoral migration of CD4+ T cells  withexpressing cytotoxic molecules 




 A Ssingle high-dose CTX is not widely used for the treatment for of human 
cancers, including hepatoceullarhepatocellular carcinoma. Rahir et al. have reported that 
a single high -dose of CTX eradicatesd the tumors arising from subcutaneous injection 
of mouse mastocytoma cells and subsequently inducesd specific tumor immunity [11].  
We have also observed that a single administration of high-dose CTX completely 
eradicatesd completely tumors in most of immunocompetent mice but not in nude mice, 
even when CTX is administered after tumor formation. Thus, further investigation of 
the effects of a single high -dose of CTX in preclinical models is warranted may warrant 
further investigation on preclinical model. Moreover, depletion of CD4+ T cells and, to a 
lesser extent, that of CD8+ T cells, attenuated CTX-induced mediated tumor eradication. 
Furthermore, immunocompetent mice rejected the same cancer cell line, but not a 
distinct onecell line, after the tumors disappearedtumor regression. Thus, in contrast to 
the widely -held view that high-dose CTX is acts as an immunosuppressant, it high-dose 
CTX can induce collaborate with T cells, particularly CD4+ T cells, to cause tumor 
regression in collaboration with T cells, particularly CD4+ T cells, and can and induce 
specific tumor immunity. 
CD4+ cytolytic T lymphocytes (CTLs) have been proposed to be present in 
under multiple circumstances several conditions [19], but are frequently viewed as 
functional variants of the classical CD4+ Th1 subset. However, Mucida and colleagues 
have proved shown that the helper T cell master regulator ThPOK, can continuously 
repress the cytotoxic CD8 lineage-associated genes in mature CD4+ helper T cells and 
that the termination ablation of ThPOK expression in mature CD4+ T cells can 
reactivate these cytotoxic CD8 lineage-associated genes [20]. These observations 
indicate the presence of CD4+ CTLs, which are distinct from other CD4+ helper T cell 
subsets. The authors havey further demonstrated that CD4+ CTLs exhibited enhanced 
LAMP1/CD107a expression as they were activatedupon activation [20]. Thus, 
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CTX-mediated infiltrated CD4+ T cells that infiltrate tumors in response to CTX 
possessed the phenotypes that are characteristic of activated CD4+ CTLs[Ed16]. 
CTLs contain secretory lysosomes, which are equipped with cytolytic proteins 
such as granzymes and perforin [21]. After the cell recognizes a target, the secretory 
lysosomes move along microtubules and polarize at the plasma membrane, where 
cytolytic proteins were are secreted into the immunological synapse formed between the 
CTLs and cancer cells [22]. Once Ggranzymes are delivered into the cytosol of cancer 
cells, and, with the help of perforin, they the granzymes then cleave a variety of 
intracellular substrates to induce cell death [23]. LAMP1/CD107a appears on the cell 
surface following the fusion of lysosomes with the plasma membrane, and therefore is 
therefore used as a functional marker of degranulation of CD8+ CTLs [24] and NK cells 
[25]. Moreover, LAMP1/CD107a is required for efficient perforin delivery to lytic 
granules and subsequent cytotoxicity [17]. We observed that infiltrated CD4+ T cells 
consistently expressed constantly higher levels of LAMP1/CD107a [Ed17]than infiltrated 
CD8+ T cells. Thus, at least in this model, compared with CD8+ T cells, infiltrated CD4+ 
T cells can translocate LAMP1/CD107a, a functional marker of cytotoxic granule 
degranulation, more efficiently than  CD8+ T cells translocate LAMP1/CD107a, a 
functional marker of cytotoxic granule degranulation. 
Circulating CD4+ T cells expressed a negligible level of LAMP1/CD107a, 
while intratumoral CD4+ T cells abundantly expressed LAMP1/CD107a, even 
immediately after CTX treatment. Thus, it is unlikelythe possibility that a small number 
of circulating LAMP1/CD107a-positive CD4+ T cells proliferated after entering into the 
tumor sites is unlikely. Consistently, adoptively -transferred CD4+ T cells did not 
proliferate within the tumor sites until four  4 days after CTX treatment. Several lines 
of evidence indicate that CD4+ CTLs can be induced by the combined action of IL-2 
and additional inflammatory cytokines, particularly type I interferon [10, 26, 27]. CTX 
can enhance the expression of IL-2 [28] and type I interferon [29]. Thus, once CD4+ T 
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cells entered into tumor sites, these cells differentiated into CD4+ CTLs under the 
influence of these cytokines. 
However, high-dose CTX was not effective in all mice and; therefore, 
improvement of itsimproving the efficacy of high-dose CTX may require additional 
measures, such as combined treatment with type I interferon [30]. We observed that 
CTX significantly enhanced the expression of CCL3 and CCL4 in the tumor sites, 
which is consistent with the a previous report ofn its the effects of CTX on peripheral 
blood and bone marrow [31]. Moreover, the transfer of splenocytes derived from 
CCR5-/- mouse-derived splenocytesmice reduced the intratumoral accumulation of 
CD4+ T cells, particularly those expressing CD107a-expressing ones. These 
observations would indicate that these chemokines directly attracted directly 
CCR5-expressing CD4+ T cells into the tumors. Thus, supplementing with the 
supplementation of CCL3 and/or CCL4 may augment the anti-tumor effects of CTX, as 
similar to our previous observations in the context of we previously observed on 
radiofrequency ablation therapy [Ed18][13]. 
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Gene Name Forward primer (5'-3') Reverse primer (5'-3') 
Granzyme B gagccaggagatgtgtgct gcacgtttggttctttgggtc 
Perforin agttcgtgccaggtgtatgg gtgggtgattgccacaggta 
CCL2 cccactcacctgctgctact tctggacccattccttcttg 
CCL3 gctgacaagctcaccctctgt ggcagtggtggagaccttca 
CCL4 cagcaccaatgggctctga gccgggaggtgtaagagaaac 
CCL5 tccaatcttgcagtcgtgtttg tctgggttggcacacacttg 
GAPDH catggccttccgtgtttccta gcggcacgtcagatcca 
HPRT tcctcctcagaccgctttt cctggttcatcatcgctaatc 
 
Table 1. Nucleotide sequences of the primers used for qRT-PCR 
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Legends to Figure Legendss 
 
Figure 1. Eradication of BNL tumors are eradicated by a single high-dose CTX 
administration. (A) Schematic representation of the experimental procedures. Five 
hundred thousand BNL cells were inoculated into the left flank of WT or nude mice. 
CTX was intraperitoneally injected at a dose of 150 mg/kg into the mice when the 
tumor volume reached 40 to 80 mm3. Tumor volumes were measured every two to three 
days after CTX treatment. (B) Tumor volumes were determined measured after CTX 
treatment in BNL tumor-bearing WT (left panel) or nude mice (right panel). The bBlue 
and red lines indicate the tumor volumes in the animals whose tumors disappeared 
regressed after CTX treatment and those whose tumors recurred after the treatment, 
respectively. The parentheses indicate the numbers of mice with a recurrent tumors 
among the total mouse numbersnumber of mice. p values were calculated with using the 
Fisher’s exact test. *, p< 0.05. (C) WT mice whose BNL tumor disappeared after CTX 
treatment or naïve WT mice subcutaneously received BNL cells and Col26 cells 
subcutaneously at into the right and left flank, respectively. Tumor-free time intervals 
were determined until 21 days after injection[Ed19]. The bBlue and red lines indicate 
re-challenged and naïve mice, respectively. Each group consisteds of six6 animals. p 
values were calculated with using the log-rank test. *, p < 0.05. (D) and (E) Mmice 
were treated, as shown in Figure 1A. The mMice received were intraperitoneally 
injected with anti-CD4 mAb (100 μg /bodyanimal), anti-CD8 mAb (200 μg 
/bodyanimal), or PBS twice,at one1 day and 14 days after CTX treatment, 
intraperitoneal injection with either anti-CD4 mAb (100 μg /body), anti-CD8 mAb (200 
μg /body), or PBS as shown in D[Ed20]. Tumor volumes were determined measured in 
mice injected with PBS (left panel), anti-CD8 mAb (middle panel), or anti-CD4 mAb 
(right panel) for 21 days after CTX injection. The bBlue and red lines indicate the 
animals whose tumors disappeared regressed after CTX treatment and those whose 
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tumors recurred after the treatment, respectively (E). The parentheses indicate the 
numbers of mice with a recurrent tumors among the total mouse numbersnumber of 
mice. p values were calculated with theusing Fisher’s exact test. *, p< 0.05; N.S., no 
significant difference.  
 
Figure 2. CTX treatment inducesd the intra-tumoral accumulation of CD4+ T cells 
expressing LAMP1/CD107a and cytotoxic molecules. (A) and (B) WT mice were 
treated as shown in Figure 1A. Tumors, draining lymph nodes (dLNs), and spleens were 
harvested to obtain single cell preparations at the indicated time points after CTX 
injection. LAMP1/CD107a expression was determined evaluated on in CD4+ cells 
(upper panel) and CD8+ cells (lower panel) by using FCM analysis. Isotype-matched 
control rat IgG was used as an isotypea control. Representative results from three 
independent experiments are shown in A. The mMean fluorescent intensity (MFI) of 
LAMP1/CD107a were determined onin CD4+ or CD8+ cells was determined. Means ± 
SD were calculated from three independent experiments and are shown in B. p values 
were calculated with using the Student’s Student’s t- test. *, p< 0.05. (C) Total RNA 
was extracted from tumor tissues three  at 3 days after CTX treatment to quantify 
granzyme B (Grz B) and perforin mRNA by qRT-PCR analysis. Data represent the 
mean ± SD from three independent experiments. p values were calculated with using the 
Student’s Student’s t- test. *, p< 0.05. (D) DoubleTwo-color immunofluorescence image 
of CD4 (red) and Grz B (green) in the tumor tissues on day 3 after CTX injection. 
Merged images with or without DAPI is are shown[Ed21]. Representative results from 
three independent experiments are shown here.  
 
Figure 3. CTX-induced induces direct intratumoral migration of naïve CD4+ T 
cells with cytotoxic phenotypes (A) CTX were was intraperitoneally administered into 
CD45.2-expressing WT mice which had received BNL cells at in the left flank, 
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similarly assimilar to the schematic [Ed22]shown in Figure 1A. Splenocytes were 
isolated from CD45.1-expressing congenic mice and were labeled with CFSE. Ten 
million labeled splenocytes were intravenously injected into the tumor-bearing mice one  
1 day after CTX injection. Tumors and dLNs were harvested four  at 4 and seven7 
days after CTX injection. (B) Single cell preparations were obtained from tumor tissues 
or dLNs, and subsequently gated based on CD4 expression. CD45.1 and CFSE 
expression among the CD4+ cells was determined assessed by FCM analysis four  at 4 
(left panels) and seven7 days (right panels) after CTX injection. Representative results 
from three independent experiments are shown here. The proportion of CD45.1+ cells 
among the total number of CD4+ cells was determined. Means ± SD were calculated 
from three independent experiments and are shown in each panel. p values were 
calculated with using the Student’s Student’s t- test. **, p< 0.01; *, p< 0.05; N.S., no 
significant difference. (C) Single cell preparations were obtained from tumor tissues 
four  at 4 and seven7 days after CTX treatment, and subsequently gated with based on 
CD4 (left panels). LAMP1/CD107a expression was determined evaluated assessed on in 
either CFSEhighCD4+CD45.1+ or CFSElowCD4+CD45.1+ cells (right panel). 
Representative results from three independent experiments are shown here.  
 
Figure 4. Enhanced CCL3 expression is enhanced in the tumor tissues after CTX 
treatment. WT mice were treated as shown in Figure 1A. (A) to (D) Total RNA was 
extracted from tumor tissues three  at 3 days after CTX treatment to quantify CCL2 
(A), CCL3 (B), CCL4 (C), or CCL5 mRNA (D) by qRT-PCR analysis. Means ± SD 
were calculated from three independent experiments and are shown here. p values were 
calculated with using the Student’s Student’s t- test. **, p< 0.01; *, p< 0.05; N.S., no 
significant difference. (E) and (F) Protein lysates were extracted from tumor tissues 
after CTX treatment to quantify CCL3 (E) and CCL4 protein content levels (F) by 
ELISA. Means ± SD were calculated from three independent experiments and are 
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shown here. p values were calculated with using the Student’s Student’s t- test. *, p< 
0.05; N.S., no significant difference. 
 
Figure 5. Essential involvement of aA CCR5-mediated signal is essential in 
CTX-mediated intratumoral migration of naïve cytotoxic CD4+ T cells. (A) WT or 
CCR5-/- mice were treated as shown in Figure 1A. Each group consisteds of at least 
five5 animals. Tumor recurrence was defined as the point at which the when tumor 
volume resumed reachedreturned to the same size as that at initial volume at the time of 
CTX treatment[Ed23]. Recurrence-free curves are shown here. p values were calculated 
with using the log-rank test. *, p < 0.05; N.S., no significant difference. (B) to (D). After 
WT mice were treated as shown in Figure 1A, 107 CFSE-labeled splenocytes from 
CFSE-labeled WT- or CCR5-/- mice-derived 107 splenocytes were intravenously 
injected into the tumor-bearing WT mice one  1 day after CTX injection (B). Tumors 
were harvested at four4 days after CTX injection to obtain single cell preparations. 
LAMP1/CD107a expression was determined assessed on in CFSEhighCD4+ cells of from 
mice receiving splenocytes from WT or CCR5-/- mice. Representative results from three 
independent experiments are shown in C. Means ± SD were calculated from three 
animals on for the proportion of CFSEhighLAMP1/CD107a+ cells among the total 
number of [Ed24]CD4+ cells and are shown in D. p values were calculated with using the 
Mann-Whitney’s U test. *,  p< 0.05. 
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Legend to Supplementary Figures 
Figure S1. Tumor volumes after treatment with different doses of CTX at different 
doses. CTX was intraperitoneally injected at the indicated doses into wild-typeWT mice 
when the tumor volume reached 40 to 80 mm3. Tumor volumes were measured every 
two to three days after CTX treatment. 
 
Figure S2. MAFO treatment induced immunogenic apoptosis of BNL cells in vitro. 
(A) and (B) After incubating BNL cells (1 x 105 cells/ml) in the medium containing in 
the presence or the absence of 30 μM mafosfamide (MAFO) for 20 hours, the labeling 
of BNL cells labeled with expression of propidium iodide (PI) and annexin-V (A) or PI 
and calreticulin (B) on BNL cells was determined measured by using FCM analysis. 
Representative images from three3 independent experiments are shown here. (C) After 
treating BNL cells as mentioned described above, the cells were incubated for another 
an additional 24 hours with fresh medium. The cConcentration of high mobility group 
box-1 (HMGB-1) in the medium was determined by using a specific ELISA (Sinotest, 
Tokyo, Japan). p values were calculated with using the Student’s Student’s t- test. *, p< 
0.05.  
 
Figure S3. CD4+ T cells in the circulation or spleen merely expressed minimal 
levels of CD107a[Ed25]. (A) and (B) Single cell preparations were obtained from the 
peripheral blood (A) and spleen (B) of both WT mice and CCR5-/- mice and were 
subsequently gated based on CD4 expression. CD107a expression among the CD4+ 
cells was determined by FCM analysis. The sSolid lines and, dashed lines indicate the 
results of from the WT mice and CCR5-/- mice, respectively. Isotype controls are shown 
represented by the gray-filled histograms. Representative results from three independent 
experiments are shown here. 
Legend to Supplementary Figures 
Figure S1. Tumor volumes after treatment with different doses of CTX. CTX was 
intraperitoneally injected at the indicated doses into WT mice when the tumor volume 
reached 40 to 80 mm3. Tumor volumes were measured every two to three days after 
CTX treatment. 
 
Figure S2. MAFO treatment induced immunogenic apoptosis of BNL cells in vitro. 
(A) and (B) After incubating BNL cells (1 x 105 cells/ml) in the presence or the absence 
of 30 μM mafosfamide (MAFO) for 20 hours, BNL cells labeled with propidium iodide 
(PI) and annexin-V (A) or PI and calreticulin (B) was measured by FCM analysis. 
Representative images from three independent experiments are shown. (C) After 
treating BNL cells as described above, the cells were incubated for an additional 24 
hours with fresh medium. The concentration of high mobility group box-1 (HMGB-1) 
in the medium was determined using a specific ELISA (Sinotest, Tokyo, Japan). p 
values were calculated using Student’s t-test. *, p< 0.05.  
 
Figure S3. CD4+ T cells in the circulation or spleen expressed minimal levels of 
CD107a[Ed1]. (A) and (B) Single cell preparations were obtained from the peripheral 
blood (A) and spleen (B) of both WT and CCR5-/- mice and were subsequently gated 
based on CD4 expression. CD107a expression among the CD4+ cells was determined by 
FCM analysis. The solid lines and dashed lines indicate the results from the WT and 
CCR5-/- mice, respectively. Isotype controls are represented by the gray-filled 
histograms. Representative results from three independent experiments are shown. 
 








